Taken together, these results provide important rationale for developing COX-2 inhibitor-based combination therapies for breast cancer patients, aiming at increasing/restoring the effectiveness of COX-2 inhibitors in breast cancer patients. The gene discussed is PTGS2; the disease is breast cancer.